Anavex Life Sciences Faces Lawsuit Over Internal Control Deficiencies
Shareholder rights law firm Robbins LLP has notified investors of a class action lawsuit filed against Anavex Life Sciences Corp. concerning alleged failures in the company's internal controls.
Robbins LLP, a law firm specializing in shareholder rights, has filed a class action lawsuit against Anavex Life Sciences Corp. The suit alleges that the company misled investors regarding deficiencies in its internal control systems. The action is open to individuals and entities who purchased Anavex Life Sciences Corp. securities between November 26, 2025, and August 28, 2026.
The complaint asserts that Anavex Life Sciences Corp., a biopharmaceutical company focused on treatments for neurological and psychiatric disorders, failed to adequately disclose issues with its internal controls. It further claims the company understated potential regulatory challenges stemming from the conduct of former CEO Christopher Missling.
Anavex Life Sciences' stock experienced declines in May 2026 following the termination of its CEO and subsequent delays in financial filings. Amended reports filed in August 2026 revealed material weaknesses in the company's internal financial reporting and disclosure controls as of September 30, 2025, and continuing through the first and second quarters of 2026.
Robbins LLP urges investors who incurred significant losses during the specified period to contact them by the November 30, 2026, lead plaintiff deadline. The firm represents investors on a contingency fee basis, meaning there are no upfront costs to participate.